Owl monkey CCR5 reveals synergism between CD4 and CCR5 in HIV-1 entry

被引：5

作者：

Nahabedian, John ^{[1
,2
]}

Sharma, Amit ^{[1
]}

Kaczmarek, Maryska E. ^{[3
]}

Wilkerson, Greg K. ^{[4
]}

Sawyer, Sara L. ^{[3
]}

Overbaugh, Julie ^{[1
,2
]}

机构：

[1] Fred Hutchinson Canc Res Ctr, Human Biol Div, 1124 Columbia St, Seattle, WA 98104 USA

[2] Univ Washington, Pathobiol, Seattle, WA 98195 USA

[3] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Vet Sci, Michale E Keeling Ctr Comparat Med & Res, Bastrop, TX USA

来源：

VIROLOGY | 2017年 / 512卷

基金：

美国国家科学基金会; 美国国家卫生研究院;

关键词：

HIV-1; Receptor; Entry; CD4; CCR5; Owl monkey; Species differences; IMMUNODEFICIENCY-VIRUS TYPE-1; AMINO-TERMINUS; CELL-SURFACE; LIVING CELLS; N-TERMINUS; ENV CLONES; INFECTIONS; VARIANTS; RECEPTOR; GP120;

D O I：

10.1016/j.virol.2017.09.018

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Studying HIV-1 replication in the presence of functionally related proteins from different species has helped define host determinants of HIV-1 infection. Humans and owl monkeys, but not macaques, encode a CD4 receptor that permits entry of transmissible HIV-1 variants due to a single residue difference. However, little is known about whether divergent CCR5 receptor proteins act as determinants of host-range. Here we show that both owl monkey (Aotus vociferans) CD4 and CCR5 receptors are functional for the entry of transmitted HIV-1 when paired with human versions of the other receptor. By contrast, the owl monkey CD4/CCR5 pair is generally a suboptimal receptor combination, although there is virus-specific variation in infection with owl monkey receptors. Introduction of the human residues 15Y and 16T within a sulfation motif into owl monkey CCR5 resulted in a gain of function. These findings suggest there is cross-talk between CD4 and CCR5 involving the sulfation motif.

引用

页码：180 / 186

页数：7

共 50 条

[1] CCR5 antagonist-resistant HIV-1 entry kinetics as a function of CD4 and CCR5 surface expression
Putcharoen, O.
Lee, S-H
Henrich, T. J.
Vanichanan, J.
Kuritzkes, D. R.
Tsibris, A. M. N.
[J]. ANTIVIRAL THERAPY, 2011, 16 : A64 - A64
[2] Identification of HIV-1 Envelope Mutations that Enhance Entry Using Macaque CD4 and CCR5
Roop, Jeremy, I
Cassidy, Noah A.
Dingens, Adam S.
Bloom, Jesse D.
Overbaugh, Julie
[J]. VIRUSES-BASEL, 2020, 12 (02):
[3] HIV entry process: Interaction between CD4 and CCR5 receptors followed by FRET
不详
[J]. EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS, 2005, 34 (06): : 610 - 610
[4] Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression
Butticaz, C
Ciuffi, A
Muñoz, MM
Thomas, J
Bridge, A
Pebernard, S
Iggo, R
Meylan, P
Telenti, A
[J]. ANTIVIRAL THERAPY, 2003, 8 (05) : 373 - 377
[5] Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication
Gong, WH
Howard, OMZ
Turpin, JA
Grimm, MC
Ueda, H
Gray, PW
Raport, CJ
Oppenheim, JJ
Wang, JM
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (08) : 4289 - 4292
[6] Two HIV-1 Variants Resistant to Small Molecule CCR5 Inhibitors Differ in How They Use CCR5 for Entry
Berro, Reem
Sanders, Rogier W.
Lu, Min
Klasse, Per J.
Moore, John P.
[J]. PLOS PATHOGENS, 2009, 5 (08)
[7] CCR5 HIV-1 vertical transmission
Shearer, WT
Kalish, LA
Zimmerman, PA
[J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 17 (02): : 180 - 181
[8] CCR5 inhibitors in HIV-1 therapy
Dorr, Patrick
Perros, Manos
[J]. EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (11) : 1345 - 1361
[9] The first structure of HIV-1 gp120 with CD4 and CCR5 receptors
Guan, Yongjun
[J]. CELL AND BIOSCIENCE, 2019, 9 (1):
[10] The first structure of HIV-1 gp120 with CD4 and CCR5 receptors
Yongjun Guan
[J]. Cell & Bioscience, 9

← 1 2 3 4 5 →